Related Experiment Videos
Current and future therapies for airway mucus hypersecretion.
1National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK.
Novartis Foundation Symposium
|February 6, 2003
Summary
Treatments for airway diseases like asthma and COPD show varied effects on mucus hypersecretion. While corticosteroids help asthma, novel therapies targeting inflammation and specific pathways are being explored for better mucus control.
Area of Science:
- Pulmonary Medicine
- Respiratory Pharmacology
Background:
- Mucus hypersecretion is a key characteristic of chronic airway inflammatory diseases such as asthma, COPD, and cystic fibrosis.
- Quantifying mucus in clinical studies is challenging, limiting understanding of current therapy effects.
Purpose of the Study:
- To review the effects of current therapies on mucus hypersecretion in airway diseases.
- To explore potential novel therapeutic strategies for managing mucus hypersecretion.
Main Methods:
- Literature review of existing therapies and emerging targets for mucus hypersecretion.
- Analysis of treatment efficacy in asthma, COPD, and cystic fibrosis.
Main Results:
- Anticholinergics may reduce mucus, while beta2 agonists and mucolytics have minimal impact.
- Corticosteroids are effective in asthma but not COPD or cystic fibrosis.
- Novel targets include tachykinin antagonists, K+ channel openers, Th2 cytokine inhibitors, and others like EGFR and MAP kinases.
Conclusions:
- Current therapies have limited or disease-specific effects on mucus hypersecretion.
- Future treatments may involve targeting specific inflammatory pathways and novel molecular targets.
- The clinical benefit of inhibiting mucus hypersecretion requires further investigation.